Two phosphorylation-independent sites on the p85 SH2 domains bind A-Raf kinase

Biochemical and Biophysical Research Communications

Volumn 290, Issue 4, 2002, Pages 1267-1274

  Fang, Yun ^a,b   Johnson, Lindsey M ^a,b   Mahon, Elizabeth S ^a,b   Anderson, Deborah H ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SASKATCHEWAN CANCER AGENCY   (Canada)

Author keywords

A Raf kinase; Non phosphorylation dependent; Non phosphotyrosine dependent; Phosphorylation independent; Phosphotyrosine independent; PI3 kinase; Protein:protein interactions; SH2 domain

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPEPTIDE; PHOSPHOPROTEIN PY751; PHOSPHOTYROSINE; PROTEIN P85; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; ENZYME BINDING; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SRC HOMOLOGY DOMAIN;

EID: 0036289728     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2002.6347     Document Type: Article

References (43)

1. Cell signaling by receptor tyrosine kinases
2. Protein-protein interactions define specificity in signal transduction
3. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors
4. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins
5. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors
6. Structural basis for the binding of proline-rich peptides to SH3 domains
7. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways
8. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo
9. SH2 domains recognize specific phosphopeptide sequences
10. Phosphopeptide binding to the N-terminal SH2 domain of the p85 alpha subunit of PI 3′-kinase: A heteronuclear NMR study
11. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase
12. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes
13. Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: An SH2 domain mimicking its own substrate
14. NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site
15. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo
16. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck
17. Interaction of the Grb10 adapter protein with the Raf1 and MEK1 kinases
18. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
19. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction
20. Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner
21. A cyclin-dependent kinase homologue, p130PITSLRE, is a phosphotyrosine-independent SH2 ligand
22. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism
23. Phosphotyrosine-independent binding of a 62-kDa protein to the src homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of Ser-59 in the lck unique N-terminal region
24. In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction
25. Phosphorylation of Cbl following stimulation with interleukin-3 and its association with Grb2, Fyn, and phosphatidylinositol 3-kinase
26. Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells
27. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A
28. Using a phage display library to identify basic residues in A-Raf required to mediate binding to the Src homology 2 domains of the p85 subunit of phosphatidylinositol 3′-kinase
29. v-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGFbeta receptor
30. A phosphatidylinositol-3 kinase binds to platelet-derived growth factor receptors through a specific receptor sequence containing phosphotyrosine
31. Interactions between SH2 domains and tyrosine-phosphorylated platelet-derived growth factor beta-receptor sequences: Analysis of kinetic parameters by a novel biosensor-based approach
32. SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange
33. Signal transduction via platelet-derived growth factor receptors
34. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
35. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
36. Protein kinases: Six degrees of separation?
37. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells
38. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases
39. Phosphorylation of c-Raf-1 by protein kinase A interferes with activation
40. Nerve growth factor-stimulated B-Raf catalytic activity is refractory to inhibition by cAMP-dependent protein kinase
41. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway
42. Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes
43. A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf